Literature DB >> 12624058

Changes in the human immunodeficiency virus p7-p1-p6 gag gene in drug-naive and pretreated patients.

Oscar Gallego1, Carmen de Mendoza, Angélica Corral, Vincent Soriano.   

Abstract

Resistance to antiretroviral agents often results from mutations within the human immunodeficiency virus (HIV) pol gene. Moreover, insertions within the p6 gag-pol region have recently been found to be involved with resistance to nucleoside analogs. Overall, we found that 21% of 156 specimens collected from HIV-infected individuals (17.6% from 74 drug-naive patients and 24.4% from 82 pretreated patients) harbored these insertions. Insertions around the KQE (Lys-Gln-Glu) motif were found in 12.2% of the pretreated patients but in none of the drug-naive subjects (P = 0.002). In contrast, insertions around the PTAP (Prol-Thre-Ala-Prol) motif were seen at similar rates ( approximately 15%) among drug-naive and pretreated patients, which supports the idea that they may be natural polymorphisms.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12624058      PMCID: PMC150303          DOI: 10.1128/JCM.41.3.1245-1247.2003

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  17 in total

Review 1.  International perspectives on antiretroviral resistance. Resistance to protease inhibitors.

Authors:  V Miller
Journal:  J Acquir Immune Defic Syndr       Date:  2001-03-01       Impact factor: 3.731

Review 2.  International perspectives on antiretroviral resistance. Nucleoside reverse transcriptase inhibitor resistance.

Authors:  C Loveday
Journal:  J Acquir Immune Defic Syndr       Date:  2001-03-01       Impact factor: 3.731

Review 3.  International perspectives on antiretroviral resistance. Nonnucleoside reverse transcriptase inhibitor resistance.

Authors:  S G Deeks
Journal:  J Acquir Immune Defic Syndr       Date:  2001-03-01       Impact factor: 3.731

4.  Emergence of zidovudine resistance in HIV-infected patients receiving stavudine.

Authors:  C de Mendoza; V Soriano; C Briones; O Gallego; P Barreiro; A Alvarez; J González-Lahoz
Journal:  J Acquir Immune Defic Syndr       Date:  2000-03-01       Impact factor: 3.731

5.  Prevalence of genotypic resistance to nucleoside analogues and protease inhibitors in Spain. The ERASE-2 Study Group.

Authors:  T Puig; M Pérez-Olmeda; A Rubio; L Ruiz; C Briones; J M Franco; M Gómez-Cano; L Stuyver; L Zamora; C Alvarez; M Leal; B Clotet; V Soriano
Journal:  AIDS       Date:  2000-04-14       Impact factor: 4.177

6.  Polymorphism of HIV type 1 gag p7/p1 and p1/p6 cleavage sites: clinical significance and implications for resistance to protease inhibitors.

Authors:  F Bally; R Martinez; S Peters; P Sudre; A Telenti
Journal:  AIDS Res Hum Retroviruses       Date:  2000-09-01       Impact factor: 2.205

7.  HIV treatment failure: testing for HIV resistance in clinical practice.

Authors:  L Perrin; A Telenti
Journal:  Science       Date:  1998-06-19       Impact factor: 47.728

Review 8.  Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel.

Authors:  C C Carpenter; D A Cooper; M A Fischl; J M Gatell; B G Gazzard; S M Hammer; M S Hirsch; D M Jacobsen; D A Katzenstein; J S Montaner; D D Richman; M S Saag; M Schechter; R T Schooley; M A Thompson; S Vella; P G Yeni; P A Volberding
Journal:  JAMA       Date:  2000-01-19       Impact factor: 56.272

9.  Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel.

Authors:  M S Hirsch; F Brun-Vézinet; R T D'Aquila; S M Hammer; V A Johnson; D R Kuritzkes; C Loveday; J W Mellors; B Clotet; B Conway; L M Demeter; S Vella; D M Jacobsen; D D Richman
Journal:  JAMA       Date:  2000-05-10       Impact factor: 56.272

10.  A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1.

Authors:  C J Petropoulos; N T Parkin; K L Limoli; Y S Lie; T Wrin; W Huang; H Tian; D Smith; G A Winslow; D J Capon; J M Whitcomb
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

View more
  13 in total

1.  Gag mutations can impact virological response to dual-boosted protease inhibitor combinations in antiretroviral-naïve HIV-infected patients.

Authors:  Lucile Larrouy; C Chazallon; R Landman; C Capitant; G Peytavin; G Collin; C Charpentier; A Storto; G Pialoux; C Katlama; P M Girard; P Yeni; J P Aboulker; F Brun-Vezinet; D Descamps
Journal:  Antimicrob Agents Chemother       Date:  2010-05-03       Impact factor: 5.191

2.  Positive impact of HIV-1 gag cleavage site mutations on the virological response to darunavir boosted with ritonavir.

Authors:  Lucile Larrouy; Sidonie Lambert-Niclot; Charlotte Charpentier; Slim Fourati; Benoit Visseaux; Cathia Soulié; Marc Wirden; Christine Katlama; Patrick Yeni; Françoise Brun-Vézinet; Vincent Calvez; Anne-Geneviève Marcelin; Diane Descamps
Journal:  Antimicrob Agents Chemother       Date:  2011-01-31       Impact factor: 5.191

3.  Elucidation of the Molecular Mechanism Driving Duplication of the HIV-1 PTAP Late Domain.

Authors:  Angelica N Martins; Abdul A Waheed; Sherimay D Ablan; Wei Huang; Alicia Newton; Christos J Petropoulos; Rodrigo D M Brindeiro; Eric O Freed
Journal:  J Virol       Date:  2015-10-28       Impact factor: 5.103

4.  The HIV-1 late domain-2 S40A polymorphism in antiretroviral (or ART)-exposed individuals influences protease inhibitor susceptibility.

Authors:  Susan M Watanabe; Viviana Simon; Natasha D Durham; Brittney R Kemp; Satoshi Machihara; Kimdar Sherefa Kemal; Binshan Shi; Brian Foley; Hongru Li; Benjamin K Chen; Barbara Weiser; Harold Burger; Kathryn Anastos; Chaoping Chen; Carol A Carter
Journal:  Retrovirology       Date:  2016-09-06       Impact factor: 4.602

5.  Non-cleavage site gag mutations in amprenavir-resistant human immunodeficiency virus type 1 (HIV-1) predispose HIV-1 to rapid acquisition of amprenavir resistance but delay development of resistance to other protease inhibitors.

Authors:  Manabu Aoki; David J Venzon; Yasuhiro Koh; Hiromi Aoki-Ogata; Toshikazu Miyakawa; Kazuhisa Yoshimura; Kenji Maeda; Hiroaki Mitsuya
Journal:  J Virol       Date:  2009-01-28       Impact factor: 5.103

6.  Impact of nelfinavir resistance mutations on in vitro phenotype, fitness, and replication capacity of human immunodeficiency virus type 1 with subtype B and C proteases.

Authors:  Luis M F Gonzalez; Rodrigo M Brindeiro; Renato S Aguiar; Helena S Pereira; Celina M Abreu; Marcelo A Soares; Amilcar Tanuri
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

7.  Amino acid insertions near Gag cleavage sites restore the otherwise compromised replication of human immunodeficiency virus type 1 variants resistant to protease inhibitors.

Authors:  Sadahiro Tamiya; Sek Mardy; Mark F Kavlick; Kazuhisa Yoshimura; Hiroaki Mistuya
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

8.  Novel tetra-peptide insertion in Gag-p6 ALIX-binding motif in HIV-1 subtype C associated with protease inhibitor failure in Indian patients.

Authors:  Ujjwal Neogi; Shwetha D Rao; Irene Bontell; Jens Verheyen; Vasudev R Rao; Sagar C Gore; Neelesh Soni; Anita Shet; Eugen Schülter; Maria L Ekstrand; Amogne Wondwossen; Rolf Kaiser; Mallur S Madhusudhan; Vinayaka R Prasad; Anders Sonnerborg
Journal:  AIDS       Date:  2014-09-24       Impact factor: 4.177

9.  PTAP motif duplication in the p6 Gag protein confers a replication advantage on HIV-1 subtype C.

Authors:  Shilpee Sharma; Prabhu S Arunachalam; Malini Menon; Viswanath Ragupathy; Ravi Vijaya Satya; Joshua Jebaraj; Shambhu Ganeshappa Aralaguppe; Chaitra Rao; Sreshtha Pal; Shanmugam Saravanan; Kailapuri G Murugavel; Pachamuthu Balakrishnan; Suniti Solomon; Indira Hewlett; Udaykumar Ranga
Journal:  J Biol Chem       Date:  2018-05-17       Impact factor: 5.157

10.  Interplay of reverse transcriptase inhibitor therapy and gag p6 diversity in HIV type 1 subtype G and CRF02_AG.

Authors:  Akinyemi I Ojesina; Beth Chaplin; Jean-Louis Sankalé; Robert Murphy; Emmanuel Idigbe; Isaac Adewole; Ernest Ekong; John Idoko; Phyllis J Kanki
Journal:  AIDS Res Hum Retroviruses       Date:  2008-09       Impact factor: 2.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.